Comparison Overview

Parragon

VS

Drug Topics

Parragon

15-17 Trim Street, Bath, Avon, BA1 1HA, GB
Last Update: 2025-11-28
Between 750 and 799

Parragon is a leading global creator of books and gifts for all ages. It is also one of the largest licensed publishers in the world, representing brands such as Disney, Marvel, Mattel, Nickelodeon, Discovery Kids and The World of Eric Carle. For more than 25 years, it has produced innovative and high-quality product formats that have delighted consumers and inspired a lifelong love of books, games, learning and play. Parragon conceives and creates more than 2000 new product concepts annually and distributes over 50 million dynamic books and gifts to more than 35 global markets.Visit www.parragon.com for further information. Parragon’s History Parragon was established in the late 1980s to supply books to the UK supermarket sector. By the late 1990s, they were the largest publisher of supermarket books in the UK and investors were anxious to finance their growth. This resulted in D.C. Thomson, a major privately owned Scottish media group, acquiring and expanding Parragon overseas. Parragon Today Parragon create and distribute over 50 million dynamic products every year in more than 25 different languages, in over 35 global markets. Parragon is proud of its diverse, award-winning, global team, consisting of more than 350 people worldwide, with UK headquarters in Bath, and offices in New York, Cologne, Melbourne, Delhi, Hong Kong, Shenzhen and Singapore. Parragon has over 100 talented designers and editors in house, supported by a wealth of world-renowned illustrators, writers, educational consultants and translators. Their teams are highly skilled in pairing exceptional commercial acumen with creative innovation, agility and energy.

NAICS: 511
NAICS Definition: Publishing Industries (except Internet)
Employees: 86
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Drug Topics

25115 Country Club Blvd, North Olmsted, 44070, US
Last Update: 2025-11-29
Between 700 and 749

Drug Topics is the top-ranked monthly retail pharmacy publication. Since 1857, pharmacist readers have received timely news on all phases of community, retail, and health-system issues and trends affecting the practice of pharmacy. We offer a forum for pharmacists to share practical ideas for better pharmacy management and patient care. We proudly serve 155,000 readers.

NAICS: 511
NAICS Definition: Publishing Industries (except Internet)
Employees: 8
Subsidiaries: 57
12-month incidents
0
Known data breaches
1
Attack type number
2

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/parragon.jpeg
Parragon
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/drug-topics.jpeg
Drug Topics
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Parragon
100%
Compliance Rate
0/4 Standards Verified
Drug Topics
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Book and Periodical Publishing Industry Average (This Year)

No incidents recorded for Parragon in 2025.

Incidents vs Book and Periodical Publishing Industry Average (This Year)

No incidents recorded for Drug Topics in 2025.

Incident History — Parragon (X = Date, Y = Severity)

Parragon cyber incidents detection timeline including parent company and subsidiaries

Incident History — Drug Topics (X = Date, Y = Severity)

Drug Topics cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/parragon.jpeg
Parragon
Incidents

No Incident

https://images.rankiteo.com/companyimages/drug-topics.jpeg
Drug Topics
Incidents

Date Detected: 08/2022
Type:Cyber Attack
Blog: Blog

Date Detected: 5/2018
Type:Breach
Attack Vector: Unauthorized Access
Blog: Blog

FAQ

Parragon company demonstrates a stronger AI Cybersecurity Score compared to Drug Topics company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Drug Topics company has historically faced a number of disclosed cyber incidents, whereas Parragon company has not reported any.

In the current year, Drug Topics company and Parragon company have not reported any cyber incidents.

Neither Drug Topics company nor Parragon company has reported experiencing a ransomware attack publicly.

Drug Topics company has disclosed at least one data breach, while Parragon company has not reported such incidents publicly.

Drug Topics company has reported targeted cyberattacks, while Parragon company has not reported such incidents publicly.

Neither Parragon company nor Drug Topics company has reported experiencing or disclosing vulnerabilities publicly.

Neither Parragon nor Drug Topics holds any compliance certifications.

Neither company holds any compliance certifications.

Drug Topics company has more subsidiaries worldwide compared to Parragon company.

Parragon company employs more people globally than Drug Topics company, reflecting its scale as a Book and Periodical Publishing.

Neither Parragon nor Drug Topics holds SOC 2 Type 1 certification.

Neither Parragon nor Drug Topics holds SOC 2 Type 2 certification.

Neither Parragon nor Drug Topics holds ISO 27001 certification.

Neither Parragon nor Drug Topics holds PCI DSS certification.

Neither Parragon nor Drug Topics holds HIPAA certification.

Neither Parragon nor Drug Topics holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

ThingsBoard in versions prior to v4.2.1 allows an authenticated user to upload malicious SVG images via the "Image Gallery", leading to a Stored Cross-Site Scripting (XSS) vulnerability. The exploit can be triggered when any user accesses the public API endpoint of the malicious SVG images, or if the malicious images are embedded in an `iframe` element, during a widget creation, deployed to any page of the platform (e.g., dashboards), and accessed during normal operations. The vulnerability resides in the `ImageController`, which fails to restrict the execution of JavaScript code when an image is loaded by the user's browser. This vulnerability can lead to the execution of malicious code in the context of other users' sessions, potentially compromising their accounts and allowing unauthorized actions.

Risk Information
cvss4
Base: 6.2
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:P/VC:N/VI:N/VA:N/SC:H/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

Mattermost versions 11.0.x <= 11.0.2, 10.12.x <= 10.12.1, 10.11.x <= 10.11.4, 10.5.x <= 10.5.12 fail to to verify that the token used during the code exchange originates from the same authentication flow, which allows an authenticated user to perform account takeover via a specially crafted email address used when switching authentication methods and sending a request to the /users/login/sso/code-exchange endpoint. The vulnerability requires ExperimentalEnableAuthenticationTransfer to be enabled (default: enabled) and RequireEmailVerification to be disabled (default: disabled).

Risk Information
cvss3
Base: 9.9
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:H/I:H/A:H
Description

Mattermost versions 11.0.x <= 11.0.2, 10.12.x <= 10.12.1, 10.11.x <= 10.11.4, 10.5.x <= 10.5.12 fail to sanitize team email addresses to be visible only to Team Admins, which allows any authenticated user to view team email addresses via the GET /api/v4/channels/{channel_id}/common_teams endpoint

Risk Information
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N
Description

Exposure of email service credentials to users without administrative rights in Devolutions Server.This issue affects Devolutions Server: before 2025.2.21, before 2025.3.9.

Description

Exposure of credentials in unintended requests in Devolutions Server.This issue affects Server: through 2025.2.20, through 2025.3.8.